The Validation Gap Inside FDA's PCCP Framework

FDA finalized its guidance on Predetermined Change Control Plans in December 2024, giving sponsors of AI-enabled devices a path to modify algorithms after clearance without filing a new submission for every update, so long as the change stays inside a pre-authorized plan (meddeviceonline.com). Paired with the agency’s broader effort to draw a clean line around what actually meets the statutory definition of a device, including its clinical decision support guidance, the direction is clear: FDA is narrowing what it reviews directly and pushing more of the ongoing validation burden onto the sponsor’s own design controls (mddionline.com).

That tradeoff works fine for the failure modes FDA’s existing framework was built to catch. It does not obviously work for the failure mode showing up in agentic systems now entering clinical and administrative workflows. As one recent analysis put it, the risk is a process failure buried underneath a correct-looking answer, a silent failure that no current FDA guidance, including the 2021 AI/ML action plan, was designed to detect (clinicaltrialvanguard.com). A benchmark score tells you the output was right. It does not tell you whether the reasoning path that produced it was stable, reproducible, or safe to run again under slightly different inputs, which is exactly the property a PCCP is supposed to bound.

This matters because PCCPs shift accountability from a point-in-time FDA review to a continuous internal monitoring obligation. The change control plan defines what the sponsor is allowed to modify and how it will verify each modification stays within approved performance bounds. If that verification protocol relies on the same benchmark-style accuracy metrics that miss silent process failures, the PCCP becomes a compliance mechanism with a blind spot built into its own monitoring layer. FDA’s design control expectations already track a rising curve of AI/ML authorizations, and that curve is accelerating precisely as agentic architectures, not static classifiers, become the norm (meddeviceonline.com). The same tension applies to software changes evaluated under existing significance thresholds for modifications to cleared devices, where the question is whether a change could significantly affect safety or effectiveness (rdworldonline.com).

For compliance and quality leaders, the decision is not whether to adopt a PCCP. It is what verification methodology sits inside it. A plan built solely on output accuracy against a benchmark set will satisfy the letter of current guidance and still leave the organization exposed to the exact failure mode regulators have not yet named. The more defensible position is to treat the PCCP’s monitoring protocol as its own design control artifact, one that tests reasoning stability and process consistency, not just output correctness, before FDA’s next guidance cycle makes that expectation explicit.

The agencies are moving fast on scope. The harder work, testing what agentic systems actually do between input and output, still belongs to the sponsor.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that PCCP verification protocols may inherit the blind spots of benchmark-based testing when applied to agentic systems—is coherent and logically constructed, but the piece treats ‘s
Source & Claim Verification	Qwen · local	cleared. Most factual claims are supported by citations, but a few lines lack direct support, such as the discussion on the rising curve of AI/ML authorizations and the specific tension with agentic architectu
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects FDA’s PCCP framework and its limitations for agentic AI but does not substantively address ISO 42001, EU AI Act, or MDR/IVDR requirements.
Technical Accuracy	Llama	cleared. The article accurately highlights the limitations of current FDA guidance on AI/ML-enabled devices, particularly with regards to agentic systems and silent process failures.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies a potential gap in current FDA guidance regarding agentic AI validation but could benefit from explicitly presenting alternative viewpoints or solutions beyond the
Novelty & Non-Duplication	Grok	cleared. The specific synthesis—that PCCP monitoring protocols inherit a structural blind spot for agentic silent process failures—is a novel framing not duplicated on the wire or in standard FDA-AI coverage,
Validation	DeepSeek	cleared. The central claim that FDA’s PCCP framework may have a validation blind spot for agentic AI’s silent process failures is logically sound and supported by cited analysis, but it remains a forward-looki

Sources cited: 12. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.